NAMPT and cancer: CHS828 was examined in a clinical trail in 1999 (Hovstadius et al., 2002b), but it wasn’t until 2008 that Olesen’s research demonstrated that the compound can block NAMPT and kill cancer cells primarily by way of depleting NAD (Olesen et al., 2008).